
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx Inc. demonstrates strong financial momentum, particularly with the recently reported 4Q24 net sales of IBSRELA reaching $53.8 million, reflecting a robust quarterly growth of 32.5% compared to 3Q24, and an overall annual total of $158.3 million. Additionally, XPHOZAH net sales for the same quarter totaled $57.2 million, marking an 11.1% increase from the previous quarter and contributing to a successful first year total of $160.9 million. The company is poised for further growth in 2025, projecting IBSRELA net sales between $240 million and $250 million, which translates to an impressive annual growth rate of approximately 52% to 58%.
Bears say
Ardelyx Inc. is facing a cautionary outlook due to projected stagnation in XPHOZAH's weekly prescriptions, remaining flat at 750, which anchors anticipated net sales for 1Q25 at only $26.7 million. The company reported a significant net loss of $39.1 million for FY2024, compounded by high operating expenses totaling approximately $361.6 million in R&D, SG&A, and cost of goods sold. Additionally, the potential deterioration of XPHOZAH's gross-to-net and risks related to market size, competition, and intellectual property could undermine future growth prospects, contributing to a negative sentiment surrounding the stock.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares